Diaceutics PLC (LON:DXRX - Get Free Report) insider Peter Keeling sold 750,000 shares of the stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of GBX 102 ($1.28), for a total value of £765,000 ($960,331.41).
Diaceutics Price Performance
Shares of LON DXRX traded down GBX 2.50 ($0.03) during midday trading on Tuesday, hitting GBX 104.50 ($1.31). The stock had a trading volume of 390,818 shares, compared to its average volume of 53,905. Diaceutics PLC has a 1 year low of GBX 79 ($0.99) and a 1 year high of GBX 110 ($1.38). The company has a quick ratio of 9.92, a current ratio of 7.99 and a debt-to-equity ratio of 3.07. The company has a market capitalization of £88.49 million, a PE ratio of 10,500.00 and a beta of 0.42. The stock has a 50 day simple moving average of GBX 99.66 and a 200-day simple moving average of GBX 94.53.
Analyst Upgrades and Downgrades
Separately, Canaccord Genuity Group restated a "buy" rating and issued a GBX 150 ($1.88) target price on shares of Diaceutics in a research report on Thursday, March 21st.
Check Out Our Latest Research Report on DXRX
Diaceutics Company Profile
(
Get Free Report)
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.
Featured Stories
Before you consider Diaceutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diaceutics wasn't on the list.
While Diaceutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
